Search
NewAmsterdam Pharma Company NV
NAMSAdd to Watchlist
33.890USD
+0.020+0.06%
Close 06/30, 16:00（ET）Quotes delayed by 15 min
3.96BMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-06-30The current earnings forecast score of NewAmsterdam Pharma Company NV is 8.75, ranking 60 out of 387 in the Biotechnology & Medical Research industry. The average price target is 45.00, with a high of 60.00 and a low of 37.00.
Analyst Rating
Based on
16
analysts
Buy
Current Rating
51.500
Target Price
+52.05%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
561
Total
5
Median
6
Average
Company name
Ratings
Analysts
NewAmsterdam Pharma Company NV
NAMS
16
Beigene Ltd
ONC
27
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
112
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is NewAmsterdam Pharma Company NV's expected revenue for the next quarter?
NewAmsterdam Pharma Company NV's expected revenue is 1.66M.
What is NewAmsterdam Pharma Company NV's price target?
Analysts forecast that NewAmsterdam Pharma Company NV's price target is USD 45.00, with the highest forecast at USD 60.00 and the lowest forecast at USD 37.00.
How have NewAmsterdam Pharma Company NVNAMS's recent earnings per share performed?
The market expectation was USD -0.40, while NewAmsterdam Pharma Company NVNAMS's earnings per share (EPS) for the previous quarter was USD -0.62. EPS for the next quarter is expected at USD -0.49.
What is the analyst rating for NewAmsterdam Pharma Company NV?
Based on the ratings of NewAmsterdam Pharma Company NV's stock from 16 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.